Steering target selectivity and potency by fragment-based de novo drug design

Tiago Rodrigues, Takayuki Kudoh, Filip Roudnicky, Yi Fan Lim, Yen Chu Lin, Christian P. Koch, Masaharu Seno, Michael Detmar, Gisbert Schneider

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)


Kinase inhibitors: Ligand-based de novo design is validated as a viable technology for rapidly generating innovative compounds possessing the desired biochemical profile. The study discloses the discovery of the most selective vascular endothelial growth factor receptor-2 (VEGFR-2) kinase inhibitor (right in scheme) known to date as prime lead for antiangiogenic drug development.

Original languageEnglish
Pages (from-to)10006-10009
Number of pages4
JournalAngewandte Chemie - International Edition
Issue number38
Publication statusPublished - Sept 16 2013


  • drug design
  • drug discovery
  • fragment-based design
  • kinase inhibitors

ASJC Scopus subject areas

  • Catalysis
  • Chemistry(all)


Dive into the research topics of 'Steering target selectivity and potency by fragment-based de novo drug design'. Together they form a unique fingerprint.

Cite this